Unravelling the intravenous and in situ vasopressin effects on the urinary bladder in anesthetized female rats: More than one vasopressin receptor subtype involved?

• Published in: European journal of pharmacology Vol. 834; pp. 109 - 117
• Main Authors: Cafarchio, Eduardo M., Auresco, Luciana C., da Silva, Luiz A., Rodart, Itatiana F., do Vale, Barbara, de Souza, Janaina S., Antonio, Bruno B., Venancio, Daniel P., Giannocco, Gisele, Aronsson, Patrik, Sato, Monica A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.09.2018
• Subjects: Anesthesia; Animals; Arterial Pressure - drug effects; Farmakologi och toxikologi; Female; Gene Expression Regulation - drug effects; Heart Rate - drug effects; Injections, Intravenous; Intravesical pressure; Kidney - drug effects; Kidney - physiology; Pharmacology and Toxicology; Rats; Rats, Wistar; Receptors; Receptors, Vasopressin - genetics; Receptors, Vasopressin - metabolism; Urinary bladder; Urinary Bladder - drug effects; Urinary Bladder - metabolism; Vasopressin; Vasopressins - administration & dosage; Vasopressins - pharmacology; Receptors; Urinary bladder; Intravesical pressure; Vasopressin
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2018.07.024

Urinary bladder dysfunctions show high prevalence in women. We focused to investigate the intravenous and in situ (topic) vasopressin effects on the bladder and also to characterize the vasopressin receptor subtypes in the bladder. Adult female Wistar rats anesthetized with isoflurane underwent to the cannulation of the femoral artery and vein, and also urinary bladder for mean arterial pressure, heart rate and intravesical pressure (IP) recordings, respectively. Doppler flow probe was placed around the renal artery for blood flow measurement. After baseline recordings, intravenous injection of saline or vasopressin at different doses (0.25, 0.5, 1.0 ng/ml/kg of b.w.); or 0.1 ml of saline or 0.1 ml of vasopressin at different doses (0.25, 0.5, 1.0 ng/ml) was randomly dropped on the bladder. In another group of rats, the UB was harvest for gene expression by qPCR and also for protein expression by Western blotting of the vasopressin receptor subtypes. We observed that either intravenous or in situ vasopressin evoked a huge increase in the IP in a dose-dependent manner compared to saline, whilst no differences were observed in the cardiovascular parameters. The genes and the protein expression of V1a, V1b and V2 vasopressin receptors subtypes were found in the bladder. Intravenous injection of V1a or V2 receptor antagonist evoked a huge fall in IP and 30 min later, i.v or in situ vasopressin evoked responses on IP were significantly attenuated. Therefore, intravenous or in situ vasopressin increases the IP due to binding in V1a or V2 receptors localized in the bladder.